Royalty Pharma (RPRX) will report Q3 2026 earnings pre-market on Nov. 4. Shares fell in September after a major setback with one of its drug candidates and have since rebounded toward their 52-week high. Analysts forecast 8.7% sales growth and essentially zero earnings growth for the quarter ended Sept. 30, though forecasts have been revised upward since August, when royalty receipts grew 14%. The article says the company's results are seen as “lumpy” due to one-time milestone payments, and updates on JNJ-4804 and daraxonrasib, or underwhelming results with Novartis's pelacarsen, could influence the market reaction. The stock trades at around 12 times forward adjusted earnings, and the article suggests its valuation could move toward a multiple in line with larger, more established biotech stocks if earnings growth becomes steadier.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
pharmaceuticalsearningsvaluation
Open a keyword to see other news on the same topic.
Related news
- 3 Reasons Royalty Pharma Is a Dividend Stock You Never Have to Sell
The article argues that Royalty Pharma suits buy-and-hold income investors for three reasons: healthcare spending tends to stay resilient through economic cycles, the company's experts select which drugs to back, and its portfolio is diversified. Royalty Pharma pays drug companies cash up front in exchange for future royalties on approved and in-development drugs, and that cash funds its shareholder distributions. Its yield is around 1.5%, slightly above the pharmaceutical sector average of roughly 1.4%. The portfolio includes 35 approved products and 16 in development, with 16 generating more than $1 billion in annual revenue and an average remaining royalty duration of around 13 years. The article acknowledges that some of its drug investments will not work out as planned.
- Cramer: I asked some tech insiders what to buy. They surprisingly said this drug stock
Jim Cramer said even tech-focused insiders favor Eli Lilly, with one predicting the drugmaker could eventually reach a $2 trillion market capitalization. Billionaire investor Ken Langone had predicted Lilly would top a $1 trillion market cap, which happened nearly a year ago; it now stands at a $1.2 trillion valuation. Lilly has emerged as the dominant GLP-1 player, and its shares closed at a record high above $1,306 on Oct. 22 before drifting lower. The CNBC Investing Club holds a hold-equivalent 2 rating on the stock, and Lilly is up 10.5% month-to-date versus 2.8% for the Dow, 0.3% for the S&P 500 and a 2.4% loss for the Nasdaq. Lilly reports third-quarter earnings Thursday, with investors watching growth in its weight-loss business, especially Foundayo.
- Why Johnson & Johnson Stock Dropped Today
Johnson & Johnson shares fell 6.8% by 12:30 p.m. ET Tuesday despite beating third-quarter earnings expectations and raising 2026 guidance. Adjusted earnings were $2.59 per share against an expected $2.53, and sales grew 5.9%. However, adjusted profit fell 7.5% and GAAP profit dropped to $0.09 per share, down 96%, due to a one-time charge for the proposed talc litigation resolution and deals involving Firefly Bio and Sail Biomedicines. Free cash flow rose more than 6% to $15.1 billion, and the company now expects 2026 sales to grow 7.4% to $101.2 billion with adjusted earnings of about $11.10 per share. The author argues the stock's valuation of more than 22x adjusted earnings and nearly 29x free cash flow is too high for roughly 7% growth, and rates it a 'sell.'
- Could Revolution Medicines Be a Millionaire-Maker Stock?
Revolution Medicines (RVMD) shares have risen more than 130% following FDA approval in August 2026 of its pancreatic cancer drug Rasonque (daraxonrasib). To turn a $25,000 investment into $1 million, the company would need a market cap of roughly $1.6 trillion, compared with about $1.2 trillion for Eli Lilly. RBC Capital Markets estimates Rasonque's peak annual sales at $11.5 billion, which at the biotech industry's average price-to-sales ratio of 8.4 would imply a market cap near $97 billion. The article says the stock is probably unlikely to reach $1.6 trillion, but it could still deliver market-beating returns for long-term investors if pipeline candidates zoldonrasib and elironrasib win approvals. Billionaire Stanley Druckenmiller's Duquesne Family Office increased its stake by 26.5% in the third quarter of 2026.
- 3 Dirt Cheap Dividend Stocks to Buy Hand Over Fist
The article argues that Pfizer, T. Rowe Price and Verizon look undervalued because the market is overreacting to their headwinds, while the S&P 500 trades at 23.5 times earnings with a 1.1% yield. Pfizer trades at 9.6 times forward earnings and offers a 5.6% dividend yield with a payout ratio just under 60%, though revenue and earnings have declined since 2022 and patent expirations such as Eliquis are pressuring shares. T. Rowe Price has a 5% forward dividend yield, a 40-year record of consecutive dividend growth and trades at 10 times forward earnings, and its pivot toward ETFs could soften the impact of a market downturn. Verizon added 550,000 net customer additions in mobility and broadband in the second quarter of 2026, but its shares have slumped on concerns about SpaceX's satellite services, and it has a 6.2% forward dividend yield at less than 9 times forward earnings.
- AstraZeneca offers compelling risk-reward into 2027 pipeline readouts, says JPMorgan
JPMorgan says AstraZeneca (LSE:AZN, NYSE:AZN) offers a compelling risk-reward opportunity ahead of late-stage readouts in 2027, which could collectively unlock more than $20 billion in non-risk-adjusted peak sales. Key studies include laroprovstat, Farxiga combinations, Datroway, puxi-sam, camizestrant and saruparib. The AVANZAR trial of Datroway has moved to Q1 2027 from Q4 2026 because progression-free survival events have not yet accumulated; JPMorgan says this could raise confidence in success, particularly in patients with the TROP2 biomarker. The stock trades at around 15 times 2027 earnings, broadly in line with European pharma, and the broker sees this as attractive given expected core earnings growth of around 10% over 2027-2030, roughly 40% ahead of the sector.
Related markets
Latest news
- Want Decades of Passive Income? 3 Energy Stocks to Buy Right Now, Starting With Energy Transfer.
The article argues dividend stocks can play a major role in long-term investor returns, citing Hartford Funds and Ned Davis Research findings that reinvested dividends account for 85% of the S&P 500's cumulative return since 1960. It highlights three energy stocks: Energy Transfer (ET), Enbridge (ENB) and ExxonMobil (XOM). Energy Transfer operates over 140,000 miles of pipeline across 44 states, with 90% of its projected earnings this year coming from long-term, fee-based contracts, and a 6.6% distribution yield. Enbridge has raised its dividend for 31 consecutive years and returned 38 billion Canadian dollars to shareholders over the past 5 years. ExxonMobil has grown its dividend for 43 years, with breakeven costs of about $40 per barrel on its advantaged assets and a goal of lowering costs to $30 per barrel by 2030.
- Pictured: Nvidia boss ‘targeted by Chinese spy’
According to US intelligence officials, Nvidia CEO Jensen Huang was courted by Alice Huang, a senior executive at Singapore-based Megaspeed, whom US officials believe passed information to Chinese intelligence agencies. The New York Times reported that Donald Trump was briefed on the matter, and Jensen Huang has been photographed with Alice Huang at events in Taiwan. A report by short-seller Culper described the two as “very close,” while Nvidia said the interactions were “not unusual or unexpected.” Megaspeed is one of Nvidia's biggest Asian customers, and officials are investigating whether it helped Chinese companies evade US chip export controls; Nvidia says those claims were “thoroughly investigated and debunked.” In January, Trump partially reversed the export ban, allowing sales of less powerful Nvidia AI chips while imposing a 25% tariff on sales to Chinese customers.
- Why Did Honeywell Aerospace Stock Drop on Thursday?
Honeywell Aerospace (HONA) shares fell 10.5% by 10:30 a.m. ET Thursday, despite beating Q3 expectations with earnings of $2.21 per share on more than $4.6 billion in sales, versus analyst forecasts of $1.86 per share. Sales rose only 2% year over year and net profit 1%, though commercial original equipment sales grew 7% on higher aircraft production, a segment that is its smallest. Commercial aftermarket sales grew 2%, while defense and space grew 1%. The company has won more than $20 billion in new contracts this year, a book-to-bill ratio of about 1.5x, but its annualized free cash flow is only about $2.6 billion. At 20x free cash flow, the article argues Honeywell needs to grow faster to justify its premium valuation.
- Walmart Blocks Its Stock From OKX-ICE Tokenized Trading Venue
Walmart, Eli Lilly, Cigna Group, Carnival and Arcos Dorados have objected to their shares being offered on OKXICE TSV, raising the total number of objecting companies to 38 from nine initially and extending the pushback into retail, health care and travel. Under the SEC's innovation exemption, if a company objects in writing within 30 days, the venue cannot make a tokenized version of its stock available for trading. OKXICE TSV, a 50-50 joint venture of Intercontinental Exchange and OKX, plans to let approved users trade tokenized U.S. stocks 24/7 on the XLayer blockchain; the exemption caps it at 75 of the largest stocks, limited to 0.25% of each stock's average daily volume, and up to 250 others at 2.5%. Major names such as Nvidia, Tesla, Apple and Amazon have not objected yet, so the list may still change.
- Amazon Earnings Prediction Market Preview: What Will Andy Jassy Say?
Amazon.com Inc. (NASDAQ:AMZN) will report third-quarter earnings after the market closes Thursday, as investors question its $220 billion capital spending plan. Analysts expect earnings of $1.97 per share on revenue of $202.2 billion, up 12%.
- ServiceNow shares plunge 24% after earnings revive AI disruption fears
ServiceNow shares fell 24% on Thursday, heading for their worst day ever, after third-quarter results revived fears that AI could disrupt traditional software business models. Revenue rose more than 20% to $4.11 billion, roughly in line with the $4.10 billion estimate, while adjusted EPS of $1.00 fell short of the $1.02 forecast. The company slightly lifted its 2026 subscription revenue outlook to between $15.78 billion and $15.79 billion, and net new AI average contract value jumped 65%. Citi's Tyler Radke said investors wanted quicker payoffs from the newly formed forward-deployed engineering team and that the inflection may not come until next year.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.